BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8205553)

  • 1. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
    Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
    Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
    Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
    Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
    Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ
    Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin increases expression of urokinase receptor by activation of the thrombin receptor.
    Yang Z; Cohen RL; Lui GM; Lawrence DA; Shuman MA
    Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2254-61. PubMed ID: 7558719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
    Bechtel MJ; Reinartz J; Rox JM; Inndorf S; Schaefer BM; Kramer MD
    Exp Cell Res; 1996 Mar; 223(2):395-404. PubMed ID: 8601416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
    Iguchi K; Tatsuda Y; Usui S; Hirano K
    Anticancer Res; 2007; 27(6B):3843-8. PubMed ID: 18225541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
    Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
    Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.